|Podcasts|May 22, 2018
What Is and Is Not in Trump's Drug Pricing Plan: An Interview With Dr Michael Chernew
American Patients First, President Donald Trump's blueprint to bring down the cost of drug pricing is the result of a campaign promise to drive down out-of-pocket costs for consumers. Those who helped craft the proposal say it represents real reform. However, critics say it goes too easy on the pharmaceutical industry.
Advertisement
American Patients First, President Donald Trump's blueprint to bring down the cost of drug pricing is the result of a campaign promise to drive down out-of-pocket costs for consumers. Those who helped craft the proposal say it represents real reform. However, critics say it goes too easy on the pharmaceutical industry.
Mary Caffrey, the managing editor of The American Journal of Managed Care® (AJMC®)’s Evidence-Based series, spoke with Harvard healthcare economist Michael E. Chernew, PhD, who is the co-editor in chief of AJMC®, to discuss elements of the Trump administration proposal to control drug prices. Chernew is also a former vice chair of the Medicare Payment Advisory Commission.
To listen, login to the website.
iTunes:
TuneIn:
Stitcher:
Listen above or through one of these podcast services:
Read more:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5
